- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04491942
Testando a adição de uma droga anticancerígena, BAY 1895344, ao tratamento quimioterápico usual (cisplatina ou cisplatina e gencitabina) para tumores sólidos avançados com ênfase no câncer urotelial
Um estudo de fase 1 do inibidor de ATR BAY 1895344 em combinação com cisplatina e com cisplatina mais gencitabina em tumores sólidos avançados com ênfase no carcinoma urotelial
This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the body (advanced). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cisplatin and gemcitabine are chemotherapy drugs that stop the growth of tumor cells by killing the cells. Combining BAY 1895344 with chemotherapy treatment (cisplatin, or cisplatin and gemcitabine) may be effective for the treatment of advanced solid tumors, including urothelial cancer.
Visão geral do estudo
Status
Condições
- Câncer de Mama Anatômico Estágio III AJCC v8
- Câncer de Mama Anatômico Estágio IV AJCC v8
- Neoplasia Sólida Maligna Avançada
- Câncer de Pulmão Estágio III AJCC v8
- Câncer de Pulmão Estágio IV AJCC v8
- Câncer Gástrico Estágio Clínico III AJCC v8
- Câncer Gástrico Estágio Clínico IV AJCC v8
- Carcinoma de Mama Triplo Negativo
- Câncer de pênis estágio IV AJCC v8
- Carcinoma Gástrico Avançado
- Carcinoma de mama avançado
- Câncer Cervical Estágio III AJCC v8
- Câncer Cervical Estágio IV AJCC v8
- Carcinoma Pulmonar de Células Não Pequenas Avançado
- Câncer de ovário estágio III AJCC v8
- Câncer de ovário estágio IV AJCC v8
- Carcinoma de ovário avançado
- Carcinoma urotelial irressecável
- Carcinoma Avançado de Cabeça e Pescoço
- Carcinoma Pulmonar Avançado de Pequenas Células
- Carcinoma Urotelial Avançado
- Câncer do ducto biliar distal estágio IV AJCC v8
- Câncer de ducto biliar intra-hepático estágio IV AJCC v8
- Carcinoma Esofágico Avançado
- Carcinoma Endometrial Avançado
- Mesotelioma Pleural Maligno Avançado
- Câncer do ducto biliar distal estágio III AJCC v8
- Carcinoma Avançado de Ducto Biliar
- Carcinoma cervical avançado
- Carcinoma peniano avançado
- Câncer de ducto biliar intra-hepático estágio III AJCC v8
- Câncer de pênis estágio III AJCC v8
- Estágio III Mesotelioma Maligno Difuso da Pleura AJCC v8
- Mesotelioma Maligno Difuso Pleural Estádio IV AJCC v8
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. To establish the safety and tolerability of the combination of cisplatin + elimusertib (BAY 1895344) in patients with advanced solid tumors.
II. To establish the safety and tolerability of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors with an emphasis on urothelial carcinoma (UC).
III. To establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344.
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetic profile of BAY 1895344 (in the doublet and triplet combinations) and gemcitabine (in the triplet) in combination with cisplatin.
II. To further evaluate the toxicity of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with UC.
III. To evaluate preliminary efficacy observed with cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors, including UC.
EXPLORATORY OBJECTIVES:
I. To evaluate the correlation of biomarkers, including deleterious deoxyribonucleic acid (DNA) damage response (DDR) gene alterations and circulating tumor (ct)DNA with responses to therapy using whole exome sequencing (WES) and messenger ribonucleic acid sequencing (RNA seq) analysis of archival formalin fixed paraffin embedded (FFPE) tissue, as well as blood.
II. To correlate drug exposure with response and/or toxicity.
OUTLINE: This is a dose-escalation study of elimusertib. Patients are assigned to 1 of 2 arms.
ARM I (DOUBLET COMBINATION): Patients receive cisplatin intravenously (IV) over 1-2 hours on day 1 and 8, and elimusertib orally (PO) once daily (QD) on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
ARM II (TRIPLET COMBINATION): Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 3 months thereafter.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
-
-
California
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Estados Unidos, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
New York
-
New York, New York, Estados Unidos, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Histologically-confirmed advanced solid tumor with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria, for which cisplatin-based therapy would be considered appropriate, including:
- Non-small cell lung cancer (NSCLC)
- UC
- Penile cancer
- Malignant pleural mesothelioma
- Small cell lung cancer
- Biliary tract cancer
- Esophageal and gastric cancers
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
- Head and neck cancer
- Triple-negative breast cancer (Her2/neu-negative, estrogen receptor [ER]/progesterone receptor [PR]-negative breast cancer)
-
For the expansion cohort of the triplet combination at MTD/RP2D only:
- Patients with histologically confirmed advanced or unresectable urothelial carcinoma are eligible
- The histology should be predominantly urothelial (>= 50% of sample evaluated contains urothelial histology)
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with gemcitabine and cisplatin in patients < 18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Availability of archival FFPE tissue
-
Prior cisplatin exposure of < 300 mg/m^2. Patients with prior cisplatin treatment must have received last cisplatin treatment > 6 months prior to enrollment
-
Prior treatment with PARP inhibitors is permitted (such as olaparib, rucaparib, or other experimental inhibitors of PARP administered in a clinical trial)
-
Prior immune checkpoint inhibitor therapy is permitted (including anti-programmed cell death protein 1 [PD-1], anti-PD-ligand [L]1 therapy, such as pembrolizumab, nivolumab, avelumab, durvalumab, atezolizumab, or anti-cytotoxic t-lymphocyte protein 4 [CTLA4] therapy such as ipilimumab, or other experimental immune checkpoint pathway inhibitors administered in a clinical trial)
-
Leukocytes >= 3,000/mcL
-
Hemoglobin >= 9 g/dL
-
Neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 2 mg/dL
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal (ULN)
-
Creatinine clearance >= 40 mL/min OR glomerular filtration rate (GFR) >= 40 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy; patients with stable brain metastases that are asymptomatic and on a stable dose of steroids are also considered eligible
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification. To be eligible for this trial, patients should be class 2B or better
-
The effects of BAY 1895344, cisplatin, and gemcitabine on the developing human fetus are unknown. For this reason and because deoxyribonucleic acid (DNA)-damage response inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Life expectancy < 6 weeks by investigator assessment
- Other active malignancy requiring treatment, except for cutaneous malignancies that require resection such as squamous cell carcinoma, basal cell carcinoma, or cutaneous melanoma, and except for prostate cancer if only on androgen deprivation therapy
- Significant peripheral neuropathy (grade 2 or higher by Common Terminology Criteria for Adverse Events [CTCAE])
- Sensorineural hearing loss (grade 2 or higher by CTCAE)
- Must NOT have had prior treatment with ATR inhibitor (prior BAY1895344 or other investigational ATR inhibitors), or current treatment with any other investigational agents
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Patients who have targeted therapies (such as PARP inhibitors) within 2 weeks prior to entering the study
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study
- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm I (cisplatin, elimusertib)
Patients receive cisplatin IV over 1-2 hours on day 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: Arm II (cisplatin, gemcitabine, elimusertib)
Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
Outros nomes:
Given IV
Outros nomes:
Given PO
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dose recomendada de fase 2 (RP2D) de BAY 1895344
Prazo: Até 21 dias a partir da data de início do tratamento
|
Até 21 dias a partir da data de início do tratamento
|
|
|
Incidence of adverse events
Prazo: Up to 28 days after completion of study treatment
|
Toxicities will be tabulated and reported according to dose level, grade, type, cycle, and attribution. Tables will be created to summarize these toxicities and side effects, overall and by cohort. Proportions and associated 95% confidence intervals will be calculated for each cohort separately. Cumulative incidence curves will be used to estimate the proportion of patients who will discontinue therapy for reasons of toxicity or general inability to tolerate the regimen. |
Up to 28 days after completion of study treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetic (PK) parameter - maximum concentration (Cmax)
Prazo: Day 2 and day 9 after treatment start date
|
Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). |
Day 2 and day 9 after treatment start date
|
|
PK parameter - area under the concentration-time curve (AUC)
Prazo: Day 2 and day 9 after treatment start date
|
Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). The impact of cisplatin on BAY 1895344 exposure will be evaluated by calculation of the AUC ratio of (day 9 / day 2) and testing non-parametrically with a null hypothesis of a ratio = 1. |
Day 2 and day 9 after treatment start date
|
|
Deoxyribonucleic acid (DNA) damage repair (DDR) mutations
Prazo: Up to 2 years
|
The association between DDR mutations and responses will be described, with a table outlining patients who achieved by progressive disease, stable disease, partial or complete responses and DDR mutation status. |
Up to 2 years
|
|
Response rate
Prazo: Up to 2 years
|
The percent of responders will be calculated and associated exact 95% confidence intervals will be constructed. |
Up to 2 years
|
|
Progression-free survival (PFS)
Prazo: Up to 2 years
|
Kaplan-Meier plots will be used to summarize PFS. |
Up to 2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Mamta Parikh, City of Hope Comprehensive Cancer Center LAO
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças do Sistema Endócrino
- Neoplasias Genitais Masculinas
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças Urogenitais Masculinas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Respiratórias
- Neoplasias por Tipo Histológico
- Doenças uterinas
- Doenças Genitais Femininas
- Doenças pulmonares
- Neoplasias das Glândulas Endócrinas
- Neoplasias Glandulares e Epiteliais
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Doenças ovarianas
- Doenças anexiais
- Neoplasias Genitais Femininas
- Distúrbios Gonadais
- Adenoma
- Neoplasias Mesoteliais
- Neoplasias pleurais
- Doenças de pele
- Doenças da mama
- Doenças do colo do útero
- Neoplasias uterinas
- Neoplasias da Mama
- Doenças penianas
- Doenças da Pele e do Tecido Conjuntivo
- Mesotelioma
- Mesotelioma, Maligno
- Neoplasias Pulmonares
- Neoplasias ovarianas
- Neoplasias do colo uterino
- Neoplasias da Mama Triplo Negativas
- Neoplasias Penianas
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Elementos
- Metais
- Metais, pesados
- Compostos de platina
- Elementos de transição
- Gemcitabina
- Cisplatina
- Citrato de 1,2-diaminociclohexanoplatina II
- Platina
- Baía 1895344
Outros números de identificação do estudo
- NCI-2020-05428
- UM1CA186717 (Concessão/Contrato do NIH dos EUA)
- NCI-2020-05428 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- PHI-117
- 10404 (Outro identificador: CTEP)
- 10404 (Outro identificador: City of Hope Comprehensive Cancer Center LAO)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .